LOXO-292 showed robust and durable activity in previously treated patients with RET-altered tumors, including NSCLC, regardless of prior therapy.
Pembrolizumab addition to platinum-based chemotherapy significantly improved PFS and OS as first-line therapy for metastatic squamous NSCLC, with benefit demonstrated regardless of PD-L1 expression level.
In this phase II trial, consolidation pembrolizumab improved time to metastatic disease or death and PFS compared with historical outcomes.
In preliminary results, first-line combination chemoimmunotherapy with durvalumab achieved an ORR of 58% and 6-month PFS of 65% in advanced MPM.
Pembrolizumab showed promising antitumor activity in patients with SCLC, particularly those with PD-L1–positive tumors.
For patients with < 1% PD-L1 tumor expression, PFS benefit with first-line nivolumab combinations was limited to those who also had high tumor mutational burden.
Addition of atezolizumab to carboplatin/paclitaxel + bevacizumab significantly prolonged PFS and OS when given as first-line therapy in advanced nonsquamous NSCLC.
In patients with advanced EGFR mutation–positive NSCLC, first-line dacomitinib significantly improved OS vs gefitinib by 7.3 months with a 24% reduced risk of death.
In this planned interim analysis, first-line pembrolizumab significantly improved OS vs CT in patients with NSCLC and PD-L1 TPS ≥ 1% with a 19% reduced risk of death.
Sequencing of plasma cfDNA noninvasively identified patients with lung cancer regardless of stage, method of diagnosis, histology, or smoking status.
Addition of atezolizumab to carboplatin/nab-paclitaxel extended PFS compared with chemotherapy alone in patients with previously untreated metastatic squamous NSCLC.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.